Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024
Get in-depth analysis of the COVID-19 impact on the Cancer/Tumor Profiling Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Cancer/Tumor Profiling Market
Request For Special PricingCancer/tumor profiling refers to the testing of specific genes/gene mutations, proteins, or other biomarkers in a blood/tissue sample, which helps in the diagnosis and treatment of cancer.
MarketsandMarkets forecasts the Cancer/Tumor Profiling market to grow from USD 7.56 billion in 2019 to USD 12.47 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 10.5% during the forecast period. The increasing incidence of cancer across the globe and the growing use of biomarkers in tumor profiling are the primary growth drivers for this market. Also, the increase in cancer research and funding initiatives and technological advancements in profiling technologies are propelling the growth of the cancer/tumor profiling market. The objective of the report is to define, describe, and forecast cancer/tumor profiling market size based on technology, cancer type, biomarker type, application, and region.
By technology, Next-Generation Sequencing (NGS) to register the highest CAGR during the forecast period
Based on technology, cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The next-generation sequencing (NGS) segment is expected to register the highest CAGR during the forecast period. The benefits of effectively exploring genetic alterations in a wide range of cancers and the identification of several differentially expressed genes and genetic/epigenetic variants as potential targets aid in the development of new biomarkers for early diagnosis of the disease. These factors are supporting the adoption of NGS technology in cancer/tumor profiling market.
By application, research application to account for the largest market share during the forecast period
Based on applications, cancer/tumor profiling market is segmented into research and clinical applications. The research applications segment accounted for the largest share of cancer/tumor profiling market in 2018. The large share of this segment is attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the growing funding for cancer research is propelling the growth of the market.
North America to hold the largest share of cancer/tumor profiling market
Cancer/tumor profiling market in North America is characterized by increasing investments for the discovery and development of biomarkers, growing demand for personalized therapeutics, rising adoption of advanced omics technologies for cancer research, rising demand for high-quality research tools for data reproducibility, and the increasing use of biomarkers for drug development. Moreover, the growing attention on developing point-of-care diagnostics for cancer detection is also contributing to market growth. These factors will drive the market growth of the North America cancer/tumor profiling market during the forecast period.
Europe to hold the largest share of the Cancer Tumor Profiling Market during the forecast period
Europe's regional segment includes Germany, France, the UK, Italy, Spain, and the Rest of Europe. The increasing prevalence of various cancer types, rising government funding for cancer research along with biomarker discovery, growing demand for personalized medicine, and the rapid adoption of technological advancements are the major growth factors of this market. Also, the growth in the European pharmaceuticals industry and increasing proteomics and genomics research for disorders like cancer and neurobiological diseases are aiding the market growth during the forecast period. Technological advancements, especially in the field of genomics and proteomics, in the European Union (EU), are further driving biomarker discovery and development in Europe. Some of the largest pharmaceutical companies in Europe are extending their support to various research programs associated with genomics and proteomics.
Market Dynamics
Driver: Increasing incidence of cancer
According to the WHO, cancer is the second-leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018. The increasing burden of cancer is attributed to several factors, including population growth and aging, as well as the changing prevalence of certain causes of cancer linked to social and economic development. Based on these statistics, basic and translational cancer research continues to be of utmost importance. The use of biomarkers can significantly enhance the accuracy of cancer diagnosis, which in turn reduces the cost of treatment. Similarly, liquid biopsy holds several benefits over traditional cancer diagnostic techniques, such as reduced costs, early prognosis, therapy monitoring, detection of tumor heterogeneity, effective against acquired drug resistance, and patient comfort (by eliminating the need for surgery). The development of new therapeutic agents tailored for a specific subset of patients based on the molecular phenotype of the malignancy has also led to a rise in the demand for personalized medicine.
Restraint: High capital investment
Within the current paradigm of personalized medicine or precision medicine, many research efforts are aimed at identifying novel biomarkers. Significant capital investments are required for the discovery, development, and validation of biomarkers used in cancer detection and prognosis. Akin to clinical trials for pharmaceuticals, translational research is a long and complicated trajectory requiring significant financial investments, and results in the rejection of several biomarker candidates. Such considerable investments to run clinical trials and address stringent regulatory requirements not only affect the ability of small companies to develop biomarkers but also severely affects innovation. This is a major factor restraining the growth of the biomarkers market and other related markets such as diagnostics (in vitro diagnostics or companion diagnostics) and personalized medicine.
Opportunity: Increasing demand for personalized medicine
Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practice and is changing the way many diseases are identified, classified, and treated. These advancements are particularly evident in the area of oncology. Moreover, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine over the last five years; this is further expected to increase by 33% over the next five years. Tumor behavior is often guided by more than a single genetic or molecular marker. Rapid advances in genomic profiling of tumors have profoundly expanded knowledge of tumor behavior and guided tailored chemotherapeutic regimens for patients. The result has been a societal and clinical push toward treatment guided by personalized medicine or precision oncology.
Challenge: Low biomarker discovery-to-approval ratio
The past two decades have witnessed significant advances in the technologies used to identify new biomarkers. Research has resulted in the identification of thousands of candidate biomarkers. Despite the advances in biomarkers in the last few years, lack of clarity regarding several essential elements restricts biomarkers from reaching their full potential in human medicine. Insufficient acceptance of robust clinical biomarker tests is one of the significant challenges. Too often, biomarkers identified in initial discovery studies have not shown reproducible activity during subsequent validation. Existing biomarkers are far from comprehensive and often lack specificity, while new biomarkers are being developed at a prolonged rate. This leads to the need for better biomarkers to improve diagnosis, guide molecularly targeted therapy, and monitor activity and therapeutic response for various cancer types.
Scope of the Report
|
Report Metric |
Details |
|
Historical Data |
2017 |
|
Base year considered |
2018 |
|
Forecast period |
20192024 |
|
Forecast units |
USD Billion (Value) |
|
Segments covered |
Technology, Cancer Type, Biomarker Type, Application, and Region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
|
Companies covered |
Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), and Foundation Medicine (US). |
The research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze the trends in each of the following sub-segments:
By Technology
- Immunoassays
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- In-Situ Hybridization (ISH)
- Microarrays
- Mass Spectrometry
- Others
By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Other Cancers
By Biomarker Type
- Genetic Biomarkers
- Protein Biomarkers
- Other Biomarkers
By Application
- Research
- Biomarker discovery
- Personalized Medicine
- Clinical
- Diagnostics
- Prognostics
- Screening
- Treatment & Monitoring
By Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players
Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Sysmex Corporation (Japan)
Recent Developments
- In May 2019, Waters QIAGEN N.V. (Germany) launched its therascreen PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) as a companion diagnostic to aid in identifying breast cancer patients.
- In May 2019, QIAGEN and leading UK-based organizations launched APIS Assay Technologies Ltd., a company that aims to improve the success rate of biomarker commercialization.
- In May 2019, Caris completed the acquisition of Phamatech, Inc., a company with a sizeable research-ready oncology network to expand industry-leading clinical trials and also undertake precision oncology trials.
- In March 2019, HTG Molecular Technologies, Inc. (US) launched the HTG EdgeSeq Mouse mRNA Tumor Response Panel in the US and Europe.
- In February 2019, Sysmex Corporation (Japan) OGT expanded its Cytocell operations with a move to a new facility in Cambridge, UK. The companys FISH probe brand will be moved to this facility, which will aid the expansion of the sales volumes and sales growth
Key Questions Addressed
- Which Cancer/Tumor Profiling applications are significant in the diagnosis/ treatment of Cancer?
- Which Cancer/Tumor Profiling technologies will witness double-digit growth during the forecast period?
- What impact will the increasing need for personalized medicine and the growing point-of-care have on this market?
- Which regions will witness a high incidence of Cancer Growth during the forecast period? What strategies will be adopted by major market players to help find solutions for Cancer/Tumor Treatment?
Frequently Asked Questions (FAQ):
Which type of technology is set to dominate the market?
The cancer/tumor profiling market is broadly segmented into immunoassays, next-generation sequencing (NGS), polymerase chain reaction (PCR), in situ hybridization, microarrays, mass spectrometry, and other technologies. In 2018, the immunoassays segment dominated the market with their rising adoption for cancer diagnosis as well as prognosis. However, in the coming years, the NGS segment is expected to witness potential growth as it offers the benefit of effectively exploring genetic alterations in a wide range of cancers and also in the identification of a number of differentially expressed genes and genetic/epigenetic variants as potential targets aid in the development of new biomarkers for early diagnosis of the disease.
What technological advancements or trends are there to look out for in the market?
The market has witnessed a paradigm shift from genomic to proteomics and other omics studies with the use of advanced technological equipment and informatics tools. Also, as opposed to traditional single omics studies, the multiple-level (genome, epigenome, transcriptome, proteome, and metabolome) approach is helping address the interrogation of cancer cells/tissues in multiple dimensions that aid in metastatic and angiogenesis studies. Along, with the growing trend of omics data integration, recent advances in in-vitro 3D culture technologies, such as organoids are opening new avenues for the development of novel, more physiological human cancer models. This is expected to aid the growth of the market by opening new avenues in regenerative and personalized medicine.
What are the opportunities available for new entrants as well as existing market players in the cancer profiling space?
Growth opportunities in emerging economies, evolving pipeline for genomic and proteomic-based cancer research, increasing focus on personalized medicine, and the increasing adoption of sequencing procedures are some of the key available opportunities for players in this market. Players in the market can focus on developing fast, reliable, and non-invasive diagnostic tools that can be used directly or by local physicians at the point-of-care to diagnose the cancer as the centralized or hospital-based procedures can be time-consuming, invasive, and require expensive equipment that need trained personnel. A new trend of miniaturized analysis systems is gaining recognition in this field for the need of rapid cancer diagnosis.
What are the major revenue pockets in the cancer/tumor profiling market currently?
The highest market share of cancer/tumor profiling is estimated to belong to the North American region; and the research segment comprises the largest share of the market among its application areas. The discovery and development of personalized medicine is expected to grow in the coming years and research is being widely undertaken to overcome the challenges of genetic testing and ethical concerns. Along with the increasing research being conducted in the field of biomarker discovery, the research in the molecular profiling field is expected to grow.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 25)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
Figure 1 Cancer/Tumor Profiling Market
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
1.6 Limitations
2 Research Methodology (Page No. - 28)
2.1 Research Approach
Figure 2 Research Design
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
Figure 3 Breakdown of Primary Interviews: By Company Type, Designations, and Region
2.1.2.3 Key Industry Insights
2.2 Market Size Estimation
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
2.3 Data Triangulation Approach
Figure 6 Data Triangulation Methodology
2.4 Assumptions for the Study
3 Executive Summary (Page No. - 36)
Figure 7 Cancer/Tumor Profiling Market, By Technology, 2019 vs 2024 (USD Million)
Figure 8 Cancer/Tumor Profiling Market, By Cancer Type, 2019 vs 2024 (USD Million)
Figure 9 Cancer/Tumor Profiling Market, By Biomarker Type, 2019 vs 2024 (USD Million)
Figure 10 Cancer/Tumor Profiling Market, By Application, 2019 vs 2024 (USD Million)
Figure 11 Geographical Snapshot of the Cancer/Tumor Profiling Market
4 Premium Insights (Page No. - 41)
4.1 Cancer/Tumor Profiling: Market Overview
Figure 12 Increasing Demand for Personalized Medicine to Drive Market Growth
4.2 Cancer/Tumor Profiling Market: Geographic Growth Opportunities
Figure 13 China to Register the Highest Growth in the Cancer/Tumor Profiling Market During the Forecast Period
4.3 Regional Mix: Cancer/Tumor Profiling Market (20192024)
Figure 14 APAC to Witness the Highest Growth During the Forecast Period (20192024)
4.4 Cancer/Tumor Profiling Market: Developed vs Developing Markets (2019 vs 2024)
Figure 15 Developing Markets to Register A Higher Growth Rate Between 2019 & 2024
5 Market Overview (Page No. - 45)
5.1 Introduction
5.2 Market Dynamics
Figure 16 Cancer/Tumor Profiling Market: Drivers, Restraints, Opportunities, and Challenges
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence of Cancer
Figure 17 Global Cancer Incidence, 20082030
5.2.1.2 Increasing Use of Biomarkers in Cancer Profiling
5.2.1.3 Increasing Cancer Research and Funding
5.2.1.4 Technological Advancements
Table 1 Market Drivers: Impact Analysis
5.2.2 Market Restraints
5.2.2.1 High Capital Investment
5.2.2.2 Technical Issues With Sample Collection and Storage
Table 2 Market Restraints: Impact Analysis
5.2.3 Market Opportunities
5.2.3.1 Increasing Demand for Personalized Medicine
Figure 18 Launch of Personalized Medicine Products, 20082016
5.2.3.2 Growing Need for Point-of-Care Diagnostics
Table 3 Market Opportunities: Impact Analysis
5.2.4 Market Challenges
5.2.4.1 Low Biomarker Discovery-To-Approval Ratio
5.2.4.2 Poor Regulatory and Reimbursement Scenario
Table 4 Market Challenges: Impact Analysis
6 Industry Insights (Page No. - 54)
6.1 Introduction
6.2 Industry Trends
Figure 19 Increasing Use of Integrated Omics Data and Growing Focus on Liquid Biopsy Tests are Key Market Trends
6.2.1 Integration of Omics Data
6.2.2 Advances in Liquid Biopsy
6.2.3 Organoids for Personalized Medicine
7 Cancer/Tumor Profiling Market, By Technology (Page No. - 57)
7.1 Introduction
Figure 20 Immunoassays to Dominate the Cancer/Tumor Profiling Market During the Forecast Period
Table 5 Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
7.2 Immunoassays
7.2.1 Immunoassay Tests Identify and Assess the Progression of Disease, Thereby Providing Information Vital for Better Therapeutic Choices
Table 6 Cancer/Tumor Profiling Market for Immunoassays, By Country, 20172024 (USD Million)
7.3 Next-Generation Sequencing
7.3.1 Advances in NGS Multiplexing Capabilities Enable One Assay to Provide A Complete Tumor Molecular Profile
Table 7 Cancer/Tumor Profiling Market for Next-Generation Sequencing, By Country, 20172024 (USD Million)
7.4 Polymerase Chain Reaction
7.4.1 Real-Time PCR Helps in the Quantification of Low-Copy Transcripts, Aiding Biomarker Identification
Table 8 Cancer/Tumor Profiling Market for Polymerase Chain Reaction, By Country, 20172024 (USD Million)
7.5 in Situ Hybridization
7.5.1 FISH is the Gold Standard for Evaluating Some Key Biomarkers and Plays A Critical Role in Guiding Targeted Therapies
Table 9 Cancer/Tumor Profiling Market for in Situ Hybridization, By Country, 20172024 (USD Million)
7.6 Microarrays
7.6.1 Microarrays are Widely Adopted in Diagnostics as They Aid in Predicting the Recurrence of Cancer After Treatment
Table 10 Cancer/Tumor Profiling Market for Microarrays, By Country, 20172024 (USD Million)
7.7 Mass Spectrometry
7.7.1 Technological Advancements are Supporting the Adoption of This Technology for Sensitive, Reliable, and Rapid Diagnosis
Table 11 Cancer/Tumor Profiling Market for Mass Spectrometry, By Country, 20172024 (USD Million)
7.8 Other Technologies
Table 12 Cancer/Tumor Profiling Market for Other Technologies, By Country, 20172024 (USD Million)
8 Cancer/Tumor Profiling Market, By Cancer Type (Page No. - 71)
8.1 Introduction
Figure 21 Breast Cancer Segment to Dominate the Cancer/Tumor Profiling Market During the Forecast Period
Table 13 Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
8.2 Breast Cancer
8.2.1 Breast Cancer is the Most Common Cancer Found Among Women
Table 14 Cancer/Tumor Profiling Market for Breast Cancer, By Country, 20172024 (USD Million)
8.3 Lung Cancer
8.3.1 Molecular Characterization of Tumors Using NGS has is A Key Tool for the Clinical Management of Nsclc Patients
Figure 22 Global Lung Cancer Incidence, 2012-2030
Table 15 Cancer/Tumor Profiling Market for Lung Cancer, By Country, 20172024 (USD Million)
8.4 Colorectal Cancer
8.4.1 IHC, PCR, Microarrays, and Imaging Technologies are Major Technologies Used in Colorectal Diagnostics
Figure 23 Colorectal Cancer Incidence Rate, Key Countries (2018)
Table 16 Cancer/Tumor Profiling Market for Colorectal Cancer, By Country, 20172024 (USD Million)
8.5 Prostate Cancer
8.5.1 Prostate-Specific Antigen is A Widely Used FDA-Approved Biomarker for Prostate Cancer Screening
Table 17 Cancer/Tumor Profiling Market for Prostate Cancer, By Country, 20172024 (USD Million)
8.6 Melanoma
8.6.1 RT-QPCR is Generally Utilized to Conduct Molecular Profiling and Analyze Biomarkers in Melanomas
Table 18 Cancer/Tumor Profiling Market for Melanoma, By Country, 20172024 (USD Million)
8.7 Other Cancers
Table 19 Cancer/Tumor Profiling Market for Other Cancers, By Country, 20172024 (USD Million)
9 Cancer/Tumor Profiling Market, By Biomarker Type (Page No. - 83)
9.1 Introduction
Figure 24 Genetic Biomarkers to Dominate the Cancer/Tumor Profiling Market During the Forecast Period
Table 20 Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
9.2 Genetic Biomarkers
9.2.1 Genetic Biomarkers are Frequently Used in Clinical Practice for Diagnosis and Prognosis
Table 21 Cancer/Tumor Profiling Market for Genetic Biomarkers, By Country, 20172024 (USD Million)
9.3 Protein Biomarkers
9.3.1 Proteomic Methods Showcase Significant Promise for the Discovery of Novel Biomarkers
Table 22 Cancer/Tumor Profiling Market for Protein Biomarkers, By Country, 20172024 (USD Million)
9.4 Other Biomarkers
Table 23 Cancer/Tumor Profiling Market for Other Biomarkers, By Country, 20172024 (USD Million)
10 Cancer/Tumor Profiling Market, By Application (Page No. - 90)
10.1 Introduction
Figure 25 Research Applications to Dominate the Cancer/Tumor Profiling Market During the Forecast Period
Table 24 Cancer/Tumor Profiling Market, By Application, 20172024 (USD Million)
10.2 Research Applications
Table 25 Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
10.2.1 Biomarker Discovery
10.2.1.1 Biomarkers are Being Exploited for the Development of Personalized Or Precision Medicine
Table 26 Cancer/Tumor Profiling Market for Biomarker Discovery, By Country, 20172024 (USD Million)
10.2.2 Personalized Medicine
10.2.2.1 The Field of Personalized Medicine is Witnessing Rapid Growth in the Area of Oncology
Table 27 Cancer/Tumor Profiling Market for Personalized Medicine, By Country, 20172024 (USD Million)
10.3 Clinical Applications
Table 28 Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
10.3.1 Diagnostics
10.3.1.1 Tumor Profiling is Rapidly Gaining Momentum in the Area of Diagnostics
Table 29 Cancer/Tumor Profiling Market for Diagnostics, By Country, 20172024 (USD Million)
10.3.2 Prognostics
10.3.2.1 Advancements in Molecular Biology are Aiding the Uptake of Tumor Profiling in This Segment
Table 30 Cancer/Tumor Profiling Market for Prognostics, By Country, 20172024 (USD Million)
10.3.3 Monitoring & Treatment
10.3.3.1 Multiplatform Profiling Analyses are Gaining Recognition for Monitoring and Treatment Among Cancer Patients
Table 31 Cancer/Tumor Profiling Market for Monitoring & Treatment, By Country, 20172024 (USD Million)
10.3.4 Screening
10.3.4.1 Screening Tests Help in Deciding If Diagnostic Tests are Required By the Patient
Table 32 Cancer/Tumor Profiling Market for Screening, By Country, 20172024 (USD Million)
11 Cancer/Tumor Profiling Market, By Region (Page No. - 101)
11.1 Introduction
Figure 26 Cancer/Tumor Profiling Market:Geographic Snapshot (2018)
Table 33 Cancer/Tumor Profiling Market, By Region, 20172024 (USD Million)
11.2 North America
Figure 27 North America: Cancer/Tumor Profiling Market Snapshot
Table 34 North America: Cancer/Tumor Profiling Market, By Country, 20172024 (USD Million)
Table 35 North America: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 36 North America: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 37 North America: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 38 North America: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 39 North America: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.2.1 US
11.2.1.1 US Dominates the North American Cancer/Tumor Profiling Market
Table 40 US: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 41 US: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 42 US: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 43 US: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 44 US: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.2.2 Canada
11.2.2.1 Growing Public-Private Partnerships to Promote Proteomics Research are Expected to Drive the Market in Canada
Table 45 Canada: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 46 Canada: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 47 Canada: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 48 Canada: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 49 Canada: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3 Europe
Figure 28 Europe: Cancer/Tumor Profiling Market Snapshot
Table 50 Europe: Cancer/Tumor Profiling Market, By Country, 20172024 (USD Million)
Table 51 Europe: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 52 Europe: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 53 Europe: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 54 Europe: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 55 Europe: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.1 Germany
11.3.1.1 Advancements Proteomics and Genomics Research are Expected to Drive Market Growth
Table 56 Germany: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 57 Germany: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 58 Germany: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 59 Germany: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 60 Germany: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.2 UK
11.3.2.1 Growth in the Life Science Industry and the Increase in Academia-Industry Partnerships Will Be the Key Factors Driving the Market
Table 61 UK: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 62 UK: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 63 UK: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 64 UK: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 65 UK: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.3 France
11.3.3.1 Growth in This Market is Primarily Driven By Increasing Investments in Life Science R&D for Infrastructural Development
Table 66 France: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 67 France: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 68 France: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 69 France: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 70 France: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.4 Italy
11.3.4.1 Increasing Investment in Cancer and Translational Research is Expected to Propel Market Growth During the Forecast Period
Table 71 Italy: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 72 Italy: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 73 Italy: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 74 Italy: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 75 Italy: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.5 Spain
11.3.5.1 Rising Incidence of Cancer and Increasing Focus on Cancer Biomarkers By Various Medical Societies to Support Market Growth in Spain
Table 76 Spain: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 77 Spain: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 78 Spain: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 79 Spain: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 80 Spain: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.3.6 Rest of Europe
Table 81 RoE: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 82 RoE: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 83 RoE: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 84 RoE: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 85 RoE: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4 Asia Pacific
Figure 29 Asia Pacific: Cancer/Tumor Profiling Market Snapshot
Table 86 Asia Pacific: Cancer/Tumor Profiling Market, By Country, 20172024 (USD Million)
Table 87 Asia Pacific: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 88 Asia Pacific: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 89 Asia Pacific: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 90 Asia Pacific: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 91 Asia Pacific: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4.1 Japan
11.4.1.1 Large Number of Research Initiatives Towards the Development of Precision Medicine Supporting Market Growth in Japan
Table 92 Japan: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 93 Japan: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 94 Japan: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 95 Japan: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 96 Japan: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4.2 China
11.4.2.1 China has the Fastest-Growing Research Sector in the APAC Region
Table 97 China: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 98 China: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 99 China: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 100 China: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 101 China: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4.3 India
11.4.3.1 Increasing Pharma R&D and Government Funding in the Biotechnology Industry are the Major Factors Driving Market Growth in India
Table 102 India: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 103 India: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 104 India: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 105 India: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 106 India: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.4.4 Rest of Asia Pacific
Table 107 RoAPAC: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 108 RoAPAC: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 109 RoAPAC: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 110 RoAPAC: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 111 RoAPAC: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.5 Latin America
11.5.1 Growing Proteomics Research in the Field of Cancer Along With the Rising Use of Advanced Techniques to Drive Market Growth
Table 112 Latin America: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 113 Latin America: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 114 Latin America: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 115 Latin America: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 116 Latin America: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
11.6 Middle East & Africa
11.6.1 Growing Genomics and Proteomics Research and Increasing Research Collaborations are Expected to Support Market Growth
Table 117 Middle East & Africa: Cancer/Tumor Profiling Market, By Technology, 20172024 (USD Million)
Table 118 Middle East & Africa: Cancer/Tumor Profiling Market, By Cancer Type, 20172024 (USD Million)
Table 119 Middle East & Africa: Cancer/Tumor Profiling Market, By Biomarker Type, 20172024 (USD Million)
Table 120 Middle East & Africa: Cancer/Tumor Profiling Market for Research Applications, By Type, 20172024 (USD Million)
Table 121 Middle East & Africa: Cancer/Tumor Profiling Market for Clinical Applications, By Type, 20172024 (USD Million)
12 Competitive Landscape (Page No. - 161)
12.1 Overview
Figure 30 Collaborations, Partnerships, and AgreementsKey Growth Strategy Adopted By Market Players From 2016 to May 2019
12.2 Competitive Leadership Mapping
12.2.1 Visionary Leaders
12.2.2 Innovators
12.2.3 Dynamic Differentiators
12.2.4 Emerging Companies
Figure 31 Cancer/Tumor Profiling Market: Competitive Leadership Mapping (2018)
12.3 Competitive Situation and Trends
12.3.1 Product Launches, Approvals, and Enhancements
Table 122 Product Launches, 20162019
12.3.2 Expansions
Table 123 Expansions, 20162019
12.3.3 Acquisitions
Table 124 Acquisitions, 20162019
12.3.4 Other Strategies
Table 125 Other Strategies, 20162019
13 Company Profiles (Page No. - 168)
(Business Overview, Products and Services Offered, Recent Developments, SWOT Analysis, and MnM View)*
13.1 Illumina, Inc.
Figure 32 Illumina, Inc.: Company Snapshot (2018)
13.2 Qiagen N.V.
Figure 33 Qiagen N.V.: Company Snapshot (2018)
13.3 Neogenomic Laboratories, Inc.
Figure 34 Neogenomic Laboratories, Inc.: Company Snapshot (2018)
13.4 Sysmex Corporation
Figure 35 Sysmex Corporation: Company Snapshot (2018)
13.5 HTG Molecular Diagnostics, Inc.
Figure 36 HTG Molecular Diagnostics, Inc.: Company Snapshot (2018)
13.6 Helomics Corporation
13.7 Genomic Health, Inc.
Figure 37 Genomic Health, Inc.: Company Snapshot (2018)
13.8 Caris Life Sciences
13.9 Nanostring Technologies, Inc.
Figure 38 Nanostring Technologies, Inc.: Company Snapshot (2018)
13.10 Ribomed Biotechnologies, Inc.
13.11 Guardant Health, Inc.
Figure 39 Guardant Health, Inc.: Company Snapshot (2018)
13.12 Foundation Medicine
Figure 40 Foundation Medicine: Company Snapshot (2018)
* Business Overview, Products and Services Offered, Recent Developments, SWOT Analysis, and MnM View Might Not Be Captured in Case of Unlisted Companies.
14 Appendix (Page No. - 219)
14.1 Insights of Industry Experts
14.2 Market Sizing & Validation Approach
14.3 Discussion Guide
14.4 Knowledge Store: Marketsandmarkets Subscription Portal
14.5 Available Customizations
14.6 Related Reports
14.7 Author Details
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of cancer/tumor profiling market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology & innovation directors, and related key executives from various key companies and organizations operating in cancer/tumor profiling market. Primary sources from the demand side include scientists, pathologists, doctors, and purchase managers of research institutes, government & private hospitals, biotechnology industries, and academic institutes. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Research Design
Research Resource Matrix
|
PERSPECTIVE |
PRIMARY RESEARCH |
SECONDARY RESEARCH |
|
|
Interviews With:
|
|
|
|
Interviews With:
|
|
Market Analysis Matrix
|
Qualitative Analysis |
Quantitative Analysis |
|
|
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by technology, by cancer type, by biomarker type, by application, and region).
Data Triangulation
After arriving at the market size, cancer/tumor profiling market was divided into several segments and subsegments. The data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, wherever applicable.
Objectives of the Study
- To define, describe, segment, and forecast global cancer/tumor profiling market by technology, cancer type, biomarker type, application, and region.
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and industry-specific challenges)
- To analyze micro-markets with respect to individual growth trends, prospects, and contributions to overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market in five main regions along with their respective key countries (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa)
- To profile key players in global market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions; new product launches, enhancements and approvals; expansions; collaborations, partnerships, & agreements; and R&D activities of the leading players in market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (Up to 5)
Geographic Analysis
- A further breakdown of the Latin America cancer/tumor profiling market into Brazil, Mexico, and Rest of Latin America
- A further breakdown of European market into Switzerland, Netherlands, and Rest of Europe.
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Cancer/Tumor Profiling Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Cancer/Tumor Profiling Market